Browsing Tag
Immunotherapy
41 posts
Can Merck’s new Keytruda injection delay biosimilar threats and change cancer care forever?
Find out how Merck’s newly FDA-approved Keytruda QLEX injectable version aims to improve cancer care with faster, more convenient treatment. Read on.
How Merck’s Keytruda became a global immunotherapy benchmark in cancer treatment
Explore Keytruda’s journey from early PD-1 research to global immunotherapy dominance, with clinical, regulatory, and innovation context shaping cancer care in 2025.
UK approves first-ever immunotherapy for type 1 diabetes — can teplizumab really delay onset by three years?
MHRA approves teplizumab, the UK’s first immunotherapy for type 1 diabetes, delaying onset by three years. See how it could reshape care pathways.
Genentech’s Lunsumio and Polivy combination triples remission in relapsed large B-cell lymphoma
Genentech's chemo-free Lunsumio and Polivy combo tripled remission time in relapsed B-cell lymphoma, signaling a shift toward outpatient oncology treatment.
CERo Therapeutics gets FDA boost for CER-1236, eyes breakthrough in AML cell therapy
CERo Therapeutics secures FDA orphan drug status for CER-1236 in AML, advancing its novel CER-T immunotherapy platform. Read what this means for investors.
Innovent’s IBI363 gains NMPA breakthrough therapy designation, boosting regulatory momentum
Innovent’s IBI363 secures NMPA breakthrough therapy designation for melanoma. Discover its clinical potential, investment outlook, and global impact.
CStone targets European expansion with EMA filing for Sugemalimab in stage III NSCLC
CStone Pharmaceuticals seeks EMA approval for sugemalimab in stage III NSCLC, aiming to expand lung cancer immunotherapy options in Europe.
Bristol Myers Squibb’s Opdualag fails to meet primary endpoint in Phase 3 trial
Bristol Myers Squibb has announced that its Phase 3 RELATIVITY-098 clinical trial, designed to evaluate Opdualag (nivolumab and…
Akeso begins Phase 3 trial of cadonilimab as consolidation therapy for non-small cell lung cancer
Akeso, Inc. (9926.HK) has initiated its pivotal Phase 3 cadonilimab trial for non-small cell lung cancer (NSCLC), marking…
City of Hope researchers unveil thymus regeneration therapy for immune system repair
Scientists at City of Hope, one of the most renowned cancer research and treatment institutions in the United…